Other languages Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Market Closed - Toronto S.E. Other stock markets 11:26:30 2024-05-02 EDT			5-day change	1st Jan Change
0.035 ^CAD	0.00%		-12.50%	0.00%

04-26	Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding	CI
04-02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-12
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-14
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors	11-13
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago	11-13
Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy	23-10-25
Appili Therapeutics Inc. Announces Demise of Rochelle Stenzler, as the Director of the Company	23-10-25
Materials stocks drag TSX to one-month low	23-09-25
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension	23-09-25
Appili gets US FDA approval for oral antibiotic solution	23-09-25
Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11
Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-23
Appili Therapeutics Net Loss of $0.08 Per Share For FY 2023	23-06-23
Appili Therapeutics Inc. Secures Contract for ATI-1701 Funding from the U.S. Air Force Academy	23-05-08
Appili Therapeutics Inc. Appoints Gary Nabors as Chief Development Officer	23-04-03
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-14
Appili Therapeutics Narrows 2022 Net Loss Compared with Final 9 Months of 2021	23-02-14
Appili Therapeutics Inc. and Saptalis Pharmaceuticals LLC Announce That FDA Accepts the ATI-1501 NDA	23-02-08
Appili Therapeutics Inc. Announces Executive Appointments	23-01-17
Appili Therapeutics Inc. Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole	23-01-13
Appili Therapeutics Inc. Announces Management Changes	22-11-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Appili Therapeutics Inc.

Equities

APLI

CA03783R1073

Other languages

Filters